GlassScriptPhysician profile
Amanda D Miller
NPI 1225775349
$1,987.37
in general payments reported to CMS, 2019-2025
37 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $188 · 2023: $906 · 2024: $412 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291 · Education: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.82 |
| Education | $508.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $312.42 | 2023 | Tukysa |
| Lilly USA, LLC | $150.24 | 2024 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $136.72 | 2023-2025 | Tagrisso |
| Astellas Pharma US INC | $116.46 | 2025 | Vyloy |
| Novartis Pharmaceuticals Corporation | $101.45 | 2022-2024 | |
| Incyte Corporation | $98.35 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Adaptive Biotechnologies Corporation | $88.25 | 2023-2025 | Clonoseq |
| Exelixis INC. | $84.99 | 2023 | |
| Abbvie INC. | $75.41 | 2023-2025 | |
| Janssen Biotech, INC. | $73.53 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Pfizer INC. | $72.46 | 2024-2025 | |
| Daiichi Sankyo INC. | $62.79 | 2022-2025 | Enhertu |
| Novocure INC. | $55.32 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.71 | 2023-2025 | |
| Amgen INC. | $41.99 | 2022-2023 | Lumakras |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.